Zidesamtinib - Nuvalent
Alternative Names: NUV-520; NVL 520Latest Information Update: 15 Apr 2024
At a glance
- Originator Nuvalent
- Class Antineoplastics; Small molecules
- Mechanism of Action ROS1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Non-small cell lung cancer; Solid tumours
- Preclinical Glioblastoma
Most Recent Events
- 08 Apr 2024 Pharmacodynamics data from a preclinical studies in Solid tumours released by Nuvalent
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 27 Feb 2024 NVL 520 receives Breakthrough Therapy status for Non-small cell lung cancer in USA